- Home
- LX vs TNYA Comparison
LX vs TNYA Comparison
Compare LX & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LX | TNYA |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 153.2M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LX | TNYA |
|---|---|---|
| Price | $0.80 | $0.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.50 | ★ $5.33 |
| AVG Volume (30 Days) | ★ 5.5M | 1.7M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 18.73% | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.74 | N/A |
| P/E Ratio | $2.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.78 | $0.53 |
| 52 Week High | $5.94 | $2.35 |
Technical Indicators
Market Signals| Indicator | LX | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 16.71 | 32.47 |
| Support Level | N/A | $0.62 |
| Resistance Level | $2.06 | $0.82 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 4.64 | 4.00 |
Price Performance
Historical ComparisonAbout LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.